DORCHESTER WEALTH MANAGEMENT Co lowered its stake in Johnson & Johnson (NYSE:JNJ) by 6.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 69,765 shares of the company’s stock after selling 4,687 shares during the quarter. Johnson & Johnson comprises 2.8% of DORCHESTER WEALTH MANAGEMENT Co’s portfolio, making the stock its 8th biggest holding. DORCHESTER WEALTH MANAGEMENT Co’s holdings in Johnson & Johnson were worth $10,177,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Financial Advantage Inc. bought a new stake in Johnson & Johnson in the 3rd quarter valued at $28,000. Kessler Investment Group LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth $29,000. Eii Capital Management Inc. purchased a new stake in Johnson & Johnson in the 3rd quarter worth $39,000. Permanens Capital L.P. boosted its holdings in shares of Johnson & Johnson by 33.3% during the 3rd quarter. Permanens Capital L.P. now owns 400 shares of the company’s stock valued at $52,000 after purchasing an additional 100 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its holdings in shares of Johnson & Johnson by 1.0% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 416,526 shares of the company’s stock valued at $58,000 after purchasing an additional 3,994 shares during the last quarter. 67.36% of the stock is currently owned by hedge funds and other institutional investors.
In other news, EVP Kathryn E. Wengel sold 2,017 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $141.07, for a total value of $284,538.19. Following the completion of the sale, the executive vice president now directly owns 51,736 shares of the company’s stock, valued at approximately $7,298,397.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Hubert Joly bought 5,000 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was bought at an average price of $141.28 per share, with a total value of $706,400.00. Following the acquisition, the director now owns 5,000 shares in the company, valued at approximately $706,400. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by corporate insiders.
Several brokerages have recently issued reports on JNJ. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 target price on the stock in a report on Wednesday, December 18th. Morgan Stanley upgraded Johnson & Johnson from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $145.00 to $170.00 in a research report on Tuesday, December 17th. Atlantic Securities raised Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Barclays upgraded Johnson & Johnson from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $140.00 to $173.00 in a report on Thursday, December 19th. Finally, Wells Fargo & Co lifted their price objective on Johnson & Johnson from $155.00 to $165.00 and gave the stock an “overweight” rating in a research note on Thursday, January 9th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Buy” and an average price target of $159.33.
Shares of NYSE:JNJ opened at $149.27 on Wednesday. The firm has a fifty day simple moving average of $144.44 and a two-hundred day simple moving average of $135.05. Johnson & Johnson has a 52 week low of $125.00 and a 52 week high of $150.17. The company has a quick ratio of 1.00, a current ratio of 1.26 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $392.60 billion, a P/E ratio of 23.32, a PEG ratio of 2.40 and a beta of 0.71.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th will be given a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 2.55%. The ex-dividend date is Monday, February 24th. Johnson & Johnson’s dividend payout ratio is 46.45%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: Support Level
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.